EN DE

Crystalvue Medical Corporation (6527) Fair Value & Analysis

Healthcare · TW · Market cap 1.8B TWD

CM Crystalvue Medical Corporation 6527 · TWO
Price76.20 TWD
Fair Value103.03 TWD
Upside+35.2%
Quality57/100
Watch Crystalvue Medical Corporation for free, get notified when fair value or trend changes. Watch for free
Expensive Growth
Solidly profitable · 15.8% net margin
negative free cash flow
4.12% dividend yield
Ranks above peers (11/12)
Wide moat 65/100
Evidence: High Range 72.12 TWD – 132.66 TWD Share as image

Fair value as of: Jul 21, 2026

From 16 valuation models · updated 20 days ago

Share price +9.8% over the past month.

A solid business, screening 35% undervalued on our models.

What matters now

  • Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.
  • A fairly wide model range (72.12 TWD to 132.66 TWD) leaves room in how you read the outcome.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

106.78 TWD 34.47 TWD Fair Value 103.03 TWD Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

60‑month range 34.47 TWD – 106.78 TWD · fair‑value band 72.12 TWD – 132.66 TWD · the 76.20 TWD price screens below the 103.03 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Crystalvue Medical Corporation (6527) currently trades at 76.20 TWD, while our model-based Fair Value estimate is 103.03 TWD, implying the stock looks roughly 35.2% undervalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Crystalvue Medical Corporation generated revenue of 913M TWD at a net margin of 15.8%. Revenue declined 16.1% year over year. It earns a return on equity of 15.1%. The stock trades on a trailing P/E of 12.5. Fundamentals as of Jul 21, 2026

Our scenario range runs from 72.12 TWD (bear case) to 132.66 TWD (bull case); at 76.20 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 16% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 35%, 6527 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Residual Income 37.52 TWD 44.65 TWD 83.60 TWD 76
Gordon GGM 17.48 TWD 31.50 TWD 43.36 TWD 70
Growth-Adj P/E 72.12 TWD 103.03 TWD 133.94 TWD 68
All 16 models by family
Earnings-Based
Graham-Dodd 39.44 TWD 121.81 TWD 161.88 TWD 54
Lynch FV 26.35 TWD 37.64 TWD 48.93 TWD 50
PEG = 1.0 26.35 TWD 37.64 TWD 48.93 TWD 46
EPV 50.34 TWD 56.49 TWD 61.62 TWD 59
Dividend Discount
Gordon GGM 17.48 TWD 31.50 TWD 43.36 TWD 70
DDM Multi-Stage 17.48 TWD 27.10 TWD 33.65 TWD 61
Multiples
P/E Multiple 87.00 TWD 116.00 TWD 145.00 TWD 63
P/S Multiple 70.22 TWD 93.62 TWD 117.03 TWD 58
P/B Multiple 73.95 TWD 98.60 TWD 123.25 TWD 55
EV/EBIT 101.60 TWD 133.73 TWD 165.86 TWD 53
EV/EBITDA 81.68 TWD 107.17 TWD 132.66 TWD 54
EV/Revenue 70.18 TWD 98.03 TWD 125.88 TWD 43
Asset-Based
NCAV (Graham) 20.29 TWD 27.19 TWD 40.58 TWD 50
Economic Profit
Residual Income 37.52 TWD 44.65 TWD 83.60 TWD 76
ROIC Compounder 52.07 TWD 61.93 TWD 73.03 TWD 67
Growth Earnings
Growth-Adj P/E 72.12 TWD 103.03 TWD 133.94 TWD 68

Widest divergence: Growth Earnings (103.03 TWD) versus Dividend Discount (27.10 TWD). Highest evidence: Residual Income (76).

Notify me when 6527 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 913M TWD
Revenue growth (YoY) -16.1%
Net margin 15.8%
Return on equity 15.1%
Free cash flow −46.1M TWD FY2025
P/E ratio 12.4
More key figures
Operating margin 20.1%
EPS (TTM) 5.70 TWD
Dividend yield 4.1%
EPS growth (YoY) -8.3%

Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 57/100

Of which business quality 56 · Market factors (momentum, volatility) 56

Profitability 58
Margins and returns on capital today
Quality Growth 52
Are margins and returns improving?
Cashflow 22
Earnings quality: real cash, not paper profit
Fin. Strength 87
Balance sheet, leverage, solvency risk
Investment 37
Disciplined investing over empire-building
Low Volatility 88
Calm price path (market factor)
Momentum 44
Price trend over the last 3–12 months (market factor)
52W Momentum 41
Distance to the 52-week high (market factor)
Net Issuance 76
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Crystalvue Medical Corporation manufactures and sells medical devices worldwide. The company offers optical coherence tomography, retinal cameras, tonometers, lens edgers, and gastroenterology supplies, as well as ODM/OEM services for automated nucleic acid extraction instrument and PCR system. It also sells minimal invasive endoscopic instrument supplies.

Full company description

Crystalvue Medical Corporation manufactures and sells medical devices worldwide. The company offers optical coherence tomography, retinal cameras, tonometers, lens edgers, and gastroenterology supplies, as well as ODM/OEM services for automated nucleic acid extraction instrument and PCR system. It also sells minimal invasive endoscopic instrument supplies. The company was founded in 2009 and is based in Taoyuan City, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Crystalvue Medical Corporation reported revenue of 949M TWD in FY2025 versus 722M TWD in FY2021, a compound +7.1%/yr. Reported net income was 147M TWD in FY2025, compounding +17.5%/yr from FY2021.

Growth Quality 43/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2025)
949M TWD
Latest YoY
+9.3%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+6.1%
Revenue +7.1%/yr
FY21 722M TWD
FY22 795M TWD
FY23 824M TWD
FY24 868M TWD
FY25 949M TWD
Net income +17.5%/yr
FY21 77.2M TWD
FY22 115M TWD
FY23 103M TWD
FY24 127M TWD
FY25 147M TWD

Watch 6527: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Crystalvue Medical Corporation Fair Value". https://www.fairvalue-calculator.com/stock/6527

Peer Group

Medical Instruments & Supplies · 203 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 57 · Above median
Fair Value upside +35% · Top 25%
Return on equity (TTM) 15% · Top 25%
Return on assets 9% · Top 25%
Net margin (TTM) 16% · Top 25%
Operating margin (TTM) 20% · Top 25%
Revenue growth -16% · Bottom 25%
Dividend yield (TTM) 4.1% · Top 25%

Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 12.4× · Cheaper than 75% of peers
P/B 1.73× · Cheaper than median
P/S (TTM) 1.95× · Cheaper than median
EV/EBITDA 9.1× · Cheaper than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 80 · sector 0
FUTURE 0 · sector 27
PAST 60 · sector 25
HEALTH 0 · sector 96
DIVIDEND 82 · sector 32

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.33 $150.04 -63%
EssilorLuxottica Société anonyme 1EL €172.45 €68.55 -60%
Medline Inc MDLN $41.11 $30.15 -27%
Becton, Dickinson and Company BDX $150.65 $103.53 -31%
Alcon Inc ALC $70.26 $39.78 -43%
ResMed Inc RMD $203.87 $187.89 -8%
West Pharmaceutical Services, Inc WST $353.71 $143.97 -59%
Straumann Holding STMN CHF 106.00 CHF 47.31 -55%
Sartorius Stedim Biotech S.A DIM €188.50 €51.16 -73%
Coloplast A/S COLOB kr 414.00 kr 382.22 -8%

Compare Crystalvue Medical Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Crystalvue Medical Corporation (6527) overvalued or undervalued?
As of Jul 21, 2026, our model estimates a fair value of 103.03 TWD versus a price of 76.20 TWD, about +35% (undervalued).
What is the fair value of 6527?
Our model-based fair value for Crystalvue Medical Corporation is 103.03 TWD (as of Jul 21, 2026), built from audited fundamentals. The current price is 76.20 TWD.
What is the quality score of 6527?
Crystalvue Medical Corporation has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Crystalvue Medical Corporation (6527)?
Crystalvue Medical Corporation reported trailing-twelve-month revenue of about 913M TWD (latest available figure, as of Jul 21, 2026).
What is the net profit margin of 6527?
The net profit margin of Crystalvue Medical Corporation is about 15.8%, meaning it keeps roughly 15.8% of revenue as net income. Based on the latest reported figures.
Does Crystalvue Medical Corporation pay a dividend?
Crystalvue Medical Corporation currently shows a dividend yield of about 4.06% relative to its recent price (as of Jul 21, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Crystalvue Medical Corporation and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.